据美国疾病控制中心(CDC)的Bernier预测,百日咳无细胞菌苗前景良好,在3～4年内可获准在市场上售销。研究者的目标是,发展与现用全菌体菌苗同样有效、但没有其副作用的新菌苗。尽管不良反应并不常见,但其严重性却导致瑞典停止常规接种、英国降低接种率、美国接种事故诉讼增加,更重要的是发病数增加。 According to Bernier, of the Centers for Disease Control and Prevention (CDC), the prospects for a B. pertussis cell-free bacterin are good and will be available for sale within three to four years. The researchers’ goal is to develop new bacterins that are as effective as the current all-bacteriophage vaccine but have no side effects. Although adverse reactions are uncommon, their severity has led to the suspension of routine immunization in Sweden, a reduction in vaccination rates in the United Kingdom, an increase in litigation in the United States for vaccination, and more importantly an increase in the incidence.